Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

The Pulmonary Hypertension Association will join more than 80 organizations globally on Monday, May 5, to recognize World Pulmonary Hypertension Day. "Early diagnosis leads to better outcomes," says ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Key points include access to medicines in medicare is reduced as the IRA is implemented; fewer drugs are covered on Medicare ...

Kolkata: At least four patients with blood leakage from the mitral valve underwent treatment using a new technique in a city ...

Figure 1: Serine elastase inhibition induces survival by reversal of pulmonary hypertension ... recommended killing without knowledge of the treatment group. Direct pulmonary artery ...

The global hydrocephalus shunts market was valued at $291.00 million in 2019 and is projected to reach $322.01 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Growth in the number of ...